6 articles
Chronic inflammation is known to play a key role in severe dry eye disease (DED), contributing to a self-perpetuating cycle of ocular surface damage. Inflammatory mediators and proteases released are
An overview of ARVO 2024 by first-time attendee, optometrist and vision researcher Dian Zhuang.
The optimal management of dry eye disease (DED) often seems an enigma. A recently published collaborative review, by Ocular Surface Laboratory (OSL) and Buchanan Ocular Therapeutics Unit (BOTU) researchers at the University of Auckland, outlined current anti-inflammatory options used in clinical man
After almost three years of Covid restrictions on international travel, it was such a pleasure to join thousands of in-person attendees at the San Diego Convention Centre for the four-day American Academy of Optometry (AAO) 2022 meeting.
Activation and elevation of inflammatory mediators is associated with the pathogenesis and progression of dry eye disease (DED)¹. The quantification of inflammatory marker levels can provide insight into the disease progression and severity and may help guide individualised treatment. However, a var